MAP PHARMACEUTICALS, INC. | |||||||||||||
(a development stage enterprise) | |||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
(In thousands, except share and per share amounts) | |||||||||||||
(Unaudited) | |||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
2010 | 2009 | 2010 | 2009 | ||||||||||
| Collaboration revenue | $ | - | $ | 8,645 | $ | - | $ | 16,129 | |||||
| Operating expenses: | |||||||||||||
| Research and development | 8,242 | 9,628 | 18,028 | 23,703 | |||||||||
| Sales, general and administrative | 3,910 | 3,437 | 7,791 | 6,245 | |||||||||
| Total operating expenses | 12,152 | 13,065 | 25,819 | 29,948 | |||||||||
| Loss from operations | (12,152) | (4,420) | (25,819) | (13,819) | |||||||||
| Other expense, net | (337) | (549) | (728) | (1,070) | |||||||||
| Net loss | (12,489) | (4,969) | (26,547) | (14,889) | |||||||||
| Net loss per share attributable to common stockholders, basic and diluted | |||||||||||||
$ | (0.47) | $ | (0.24) | $ | (1.01) | $ | (0.72) | ||||||
| Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted | |||||||||||||
26,480,166 | 20,699,343 | 26,167,861 | 20,641,878 | ||||||||||
